Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
09/28/2010
Trade Name:
Kapvay Extended Release Tablets
Generic or Proper Name (*):
clonidine
Indications Studied:
Treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications
Therapeutic Category:
Non-stimulant ADHD treatment
Ages Studied:
6-17 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
197
No Centers:
22
No Countries:
1
BPCA(B), PREA(P):
P
Asian:
0
Black:
54
Other:
15
White:
106
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
22
Non-Hispanic/Non Latino:
0
Countries:
US
-
-